Researcher
Diether Lambrechts
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Morphological sciences, Oncology
- See also: Diether Lambrechts (KU Leuven)
Affiliations
- Laboratory of Translational Genetics (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2017 → Today - VIB-KU Leuven Center for Cancer Biology (Research Center)
Responsible
From1 Jan 2017 → Today - Lambrechts Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory of Translational Genetics (VIB-KU Leuven) (Division)
Member
From1 Jan 2012 → Today - Centre for Molecular and Vascular Biology (Division)
Member
From1 Oct 2003 → 30 Sep 2005 - Department of Cellular and Molecular Medicine (Department)
Member
From1 Oct 1999 → 30 Sep 2003
Projects
1 - 7 of 7
- EXPANDing Immune Cells and their Tumor Antigens during checkpoint immunotherapyFrom1 Jan 2023 → TodayFunding: HORIZON.1.1 - European Research Council (ERC)
- VIB Grant for Lambrechts Lab_Period:2022-01-01-2026-12-31From1 Jan 2022 → TodayFunding: FRI - Project driven research
- CIRCULATING TUMOR DNA AS AN EPIGENETIC BIOMARKER FOR TUMOR RESPONSE’ — ‘INITIATOR’ - ERC POCFrom1 Aug 2020 → 31 Jan 2022Funding: HORIZON.1.1 - European Research Council (ERC)
- RESISTANCE UNDER COMBINATORIAL TREATMENT IN ER+ AND ER- BREAST CANCER.’ — ‘RESCUER’From1 Jan 2020 → TodayFunding: Other EU initiatives out of framework
- 'Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer: Systems based patient stratification solutions’ — ‘COLOSSUS’From1 Jan 2018 → 31 Dec 2022Funding: Other EU initiatives out of framework
- Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics (GLIOTRAIN) - Marie Sklodowska-Curie actions (ITN)From1 Sep 2017 → 31 Aug 2021Funding: HORIZON.1.2 - Marie Skłodowska-Curie-actions (MSCA)
- VIB Grant for Lambrechts Lab_Period:2017-01-01-2021-12-31From1 Jan 2017 → 31 Dec 2021Funding: FRI - Project driven research
Publications
11 - 20 of 230
- Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study.(2023)
Authors: Diether Lambrechts
Pages: 475-491 - Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features.(2023)
Authors: Diether Lambrechts
Pages: 3729-3743 - Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.(2023)
Authors: Diether Lambrechts, Francesca Lodi
Pages: 1327-1338 - Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy.(2023)
Authors: Linqian Weng, Gabriele Bergers, Diether Lambrechts, Francesca Lodi, Gonca Dilcan Durdag
Pages: 300-314 - Tumor endothelial cell autophagy is a key vascular-immune checkpoint in melanoma.(2023)
Authors: Jelle Verhoeven, Kathryn Jacobs, Francesca Rizzollo, Francesca Lodi, Yichao Hua, Joanna Pozniak, Diede Houbaert, Sanket More, Mathieu Bertrand, Jean-Christophe Marine, et al.
Pages: e18028 - The pulmonary vasculature in lethal COVID-19 and idiopathic pulmonary fibrosis at single-cell resolution.(2023)
Authors: Laura de Rooij, Lisa Becker, Laure-Anne Teuwen, Bram Boeckx, Subramanian Abhishek x, Sébastien Dumas, Elda Meta, Mila Borri, Liliana Sokol, Anh Co Khanh Truong, et al.
Pages: 520-535 - Single-cell profiling and zebrafish avatars reveal LGALS1 as immunomodulating target in glioblastoma.(2023)
Authors: Fabio Stanchi, Bram Boeckx, Diether Lambrechts, Ludo Van Den Bosch, Holger Gerhardt
Pages: e18144 - Transcription factor NKX2-1 drives serine and glycine synthesis addiction in cancer.(2023)
Authors: Jan Cools, Diether Lambrechts
Pages: 1862-1878 - Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry.(2023)
Authors: Diether Lambrechts
Pages: 7 - Metabolomic and transcriptomic response to imatinib treatment of gastrointestinal stromal tumour in xenograft-bearing mice.(2023)
Authors: Diether Lambrechts, Bram Boeckx
Pages: 101632
Patents
1 - 10 of 10
- DISEASE DETECTION IN LIQUID BIOPSIES (Inventor)
- BIOMARKERS PREDICTING RESPONSE OF BREAST CANCER TO IMMUNOTHERAPY (Inventor)
- DISEASE DETECTION IN LIQUID BIOPSIES (Inventor)
- PREDICTING CHRONIC ALLOGRAFT INJURY THROUGH AGE-RELATED DNA METHYLATION (Inventor)
- PREDICTING CHRONIC ALLOGRAFT INJURY THROUGH AGE-RELATED DNA METHYLATION (Inventor)
- RETROTRANSPOSON BIOMARKERS (Inventor)
- RETROTRANSPOSON BIOMARKERS (Inventor)
- DISEASE DETECTION IN LIQUID BIOPSIES (Inventor)
- DETECTION OF OVARIAN CANCER IN LIQUID BIOPSIES (Inventor)
- PREDICTING CHRONIC ALLOGRAFT INJURY THROUGH AGE-RELATED DNA METHYLATION (Inventor)